TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plaque accumulation (PLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cTnT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hemodynamics stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adult functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uptake of pre-ARV care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Time for balloon expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Bishop scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of oxytocin use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: muscle thickness of the quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of patient‐provider communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Accuracy of self‐perceived risk for diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of self‐perceived risk for colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: DTPA clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Interinstrument agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of influenza per 1000 person-days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean NRS pain scores upon arrival to the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative opioid consumption over 24 hr
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microbial counts and endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dialysate Sodium, Chloride and Bicarbonate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of m-PPPASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion about goals of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Limitation of life-sustaining treatment upon discharge
Endpoint domain: Mortality/survival
Primary endpoint: contamination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: intervention enactment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean number of prescribed antihypertensive agents per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documented reductions of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of micronucleated cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reintervention
Endpoint domain: Adverse events/effects
Primary endpoint: eGFR impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of relief from muscle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elapsed time before exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postexercise blood lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total area under the time‐concentration curve (AUC) of rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak plasma concentration of rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral clearance of rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perception of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rate to NADH
Endpoint domain: Adverse events/effects
Primary endpoint: Positive attitudes to dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Empathy improvements
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported sense of competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: comfort in patient management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bone Mineral Density (BMD) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct performance of bedside check during transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in DAS28‐ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American College of Rheumatology 20/50/70 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire‐Disability Index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical attachment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positional nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptoms of vertigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Follow-up vestibular test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart Rate (HR) response to adenosine and regadenoson
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vasodilation response to Ach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Therapeutic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in second or third degree tears or episiotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction in instrumental deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Visual Analogue Scale (VAS) of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average length of stay after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Overall Response Rate (ORR) in mutation-positive samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor size decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeling more in control of their mental health problem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Onset of Ocular Angiogenesis Glaucoma (OAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall toxicity of the definitive CTx/RTx protocol
Endpoint domain: Adverse events/effects
Primary endpoint: Actuarial survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Loco-regional control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of postspinal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day retention for ARV pickups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 60-day retention for ARV pickups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 90-day retention for ARV pickups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Non-adherence to medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of school-breakfast reports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of school-lunch reports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rates for stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall category of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of lethal A‐GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: survival at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: maximum decrease in forced expiratory volume in the first second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: trough serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of breastfeeding within one hour of birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained exclusive breastfeeding rates at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pleasantness of exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fatigue during exercise
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Plasma concentrations of palmitoylethanolamide (PEA) and stearoylethanolamide (SEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood states (happiness and fatigue)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Image quality of ascending aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PO(2)/FiO(2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FiO(2) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total leiomyoma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum haemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of time with pH below 4 in the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of reflux episodes >5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: decreased CLASI‐A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute bioavailability of caplets in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability of caplets in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against Salmonella Typhi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful notification rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative survival rates of GIC restorations
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative survival rates of pulp
Endpoint domain: Mortality/survival
Primary endpoint: urethral fistula rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: skin dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: acute skin infection
Endpoint domain: Adverse events/effects
Primary endpoint: 26-week mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: plaque index bracket score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-FXa activity (UI/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETP (nmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LT and TTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with high Ki-67 labeling in the parabasal layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of (18)F‐FDG flux to transport (K(i)/K(1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: N20m recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of abnormal results in NIPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: False positive results in NIPT
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety reduction (STAI I and STAI II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression reduction (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in pregnancy related experience (PEQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: average power increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average velocity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of pulmonary disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PQ length measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New systemic corticosteroid prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Systemic corticosteroid burden
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: spontaneous onset of labour (SOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of new CNV development in fellow eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: risk of smoking relapse within 12 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Landing Error Scoring System scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IVF birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum sector pressure at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum sector pressure at maximum squeezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetry index at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetry index at maximum squeezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood Hb concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: StO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: oxygen extraction fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Elimination of paroxysmal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Achievement of seizure termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Survival status
Endpoint domain: Mortality/survival
Primary endpoint: influx of total cells in bronchoalveolar lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: influx of neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: influx of eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response rate (>or= 50% decrease in 17‐item HAMD total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of overall and treatment‐related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients discontinued prematurely due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for oral nutritional supplements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Taste of oral nutritional supplements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral sensation of oral nutritional supplements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PISFOP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCFOP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical parameters (GI, BOP, PPD, PAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for needle type
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain experienced during injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CHO and TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: renal risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Performance on knot tying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAS patient global
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUSCAN pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: uptake of screening activities
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Distress levels as measured by the DRAM questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sense of coherence (SOC) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Manageability scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decreased frequency of memory failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory functioning improvements (RBMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Load to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Load to 2 mm of displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean changes in BPI Average Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS overall pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of discontinuation due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in activity limitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of chest compressions per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-corrected efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V 15 of the bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean dose to both kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximal dose to the spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of total cholesterol to HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain levels after procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptance of treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of apprehension
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intraarterial density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to substantial pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cumulative survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Healing maintenance rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean time to first recurrence of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom-free rate at month 6
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of invasive GBS infections in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Probability of malignant infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes